Paul Hastings, Gibson Dunn Steer $739M Ligand-Xoma Deal
Ligand Pharmaceuticals said it plans to purchase XOMA Royalty in a $739 million deal combining the two biotechnology royalty aggregator companies advised by Gibson Dunn & Crutcher LLP and Paul Hastings...To view the full article, register now.
Already a subscriber? Click here to view full article